Table 1.

Comparison of changes in BCVA among laser and anti-VEGF studies

	Photocoagulation	Ranibizumab		Bevacizumab		Aflibercept
	DRCR.net22 n = 272 2 years	READ238 n = 37 2 years	RESTORE16 n = 115 1 year	BOLT40 n = 37 2 years	PACORES41 n = 141 2 years	DA VINCI42 n = 45 1 year
Visual acuity
≥3 line improvement	20%	24.0%	23.0%	32.0%	–	42.2%
≥2 line improvement	34%	–	37.0%	49.0%	53%	62.0%
≥2 line loss	19%	–	4%	–	4%	–
≥3 line loss	13%	–	<1%	0.0%	–	0%
Mean letter improvement	2	7.7	6.1	8.6	11.8	12.0

Abbreviations: BCVA, best-corrected visual acuity; VEGF, vascular endothelial growth factor.